Abstract
Objective
This study aimed to determine the expression level of biglycan in different lesion properties of endometrium and to investigate the possible function and prognostic value of biglycan in endometrial cancer.
Methods
Immunohistochemical staining (IHC) and quantitative realtime reverse transcription polymerase chain reaction (qRT-PCR) were used to determine the protein and mRNA levels of biglycan in human normal endometrium, atypical hyperplasia endometrium, and endometrial cancer tissue samples. The expression of biglycan in serum and peritoneal washings was detected by ELISA method. Then we analyzed the correlation of biglycan expression with clinicopathological parameters in endometrial cancer.
Results
(1) Biglycan was overexpressed in endometrial cancer, especially in cancerous mesenchyme. Moreover, biglycan expression was significantly correlated with histopathological grade and FIGO stage of endometrial cancer; (2) Biglycan expression level in sera and peritoneal washings was significantly higher in endometrial cancer patients; otherwise, Serum expression correlated with clinicopathological parameters of endometrial cancer; (3) Higher level expression of biglycan in cancerous mesenchyme correlated with poor prognosis of endometrial cancer.
Conclusions
Biglycan might play a role in the progression of human endometrial cancer and it might be a useful molecular marker for the prognosis of endometrial cancer. This research is an initial step towards biglycan as a potential prognosis marker in endometrial cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Van der Horst PH, Wang Y, Vandenput I et al (2012) Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer. PLoS One 7(1):e30840
Iozzo R (1999) The biology of the small leucine-rich proteoglycans: functional network of interactive proteins [review]. J Biol Chem 274:18843–18846
Ameye L, Aria D, Jepsen K et al (2002) Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis. FASEB J 16(7):673–680
Weber CK, Sommer G, Michl P et al (2001) Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. Gastroenterology 121(3):657–667
Gotte M, Sofeu Feugaing DD, Kresse H (2004) Biglycan is internalized via a chlorpromazine-sensitive route. Cell Mol Biol Lett 9(3):475–481
Nishino R, Honda M, Yamashita T et al (2008) Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J Hepatol 49(2):207–216
Pan S, Cheng L, White JT et al (2009) Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. OMICS 13(4):345–354
Modolo F, Biz MT, Martins MT et al (2010) Expression of extracellular matrix proteins in adenomatoid odontogenic tumor. J Oral Pathol Med 39(3):230–235
Mikula M, Rubel T, Karczmarski J et al (2010) Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors. Funct Integr Genomics 11:215–224
Wang B, Li GX, Zhang SG et al (2011) Biglycan expression correlates with aggressiveness and poor prognosis of gastric cancer. Exp Biol Med 236(11):1247–1253
Yamamoto K, Ohga N, Hida Y et al (2012) Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. Br J Cancer 106(6):1214–1223
Gallagher J (2007) Messages in the matrix: proteoglycans go the distance. Dev Cell 13(2):166–167
Gu X, Ma Y, Xiao J et al (2012) Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers. Clin Exp Med 12(3):195–199
Wu Z, Aron AW, Macksoud EE et al (2012) Uterine dysfunction in biglycan and decorin deficient mice leads to dystocia during parturition. PLoS One 7(1):e29627
Chen WB, Lenschow W, Tiede K et al (2002) Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells. J Biol Chem 277(39):36118–36128
Mikula M, Rubel T, Karczmarski J et al (2010) Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors. Funct Integr Genomics 11:215–224
Galamb O, Sipos F, Spisa′k S et al (2009) Potential biomarkers of colorectal adenoma-dysplasia carcinoma progression: mRNA expression profiling and in situ protein detection on TMAs reveal 15 sequentially upregulated and downregulated genes. Cell Oncol 31:19–29
Acknowledgments
The work was supported by National Natural Science Foundation of China [81372808(J.J), 81072121(J.J) and 81173614(L.QT)], as well as Science and Technology Development planning of Shandong [2011GSF12122(X.Z)] and [2012G0021823 (J.J)].
Conflict of interest
We declare that we have no conflict of interest with other people or organisations. All authors have contributed significantly to this work, and that all authors are in agreement with the content of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Y. Liu and W. Li contributed equally.
We also state that we have had full control of all primary data and that we agree to allow the Journal to review our data if requested.
Rights and permissions
About this article
Cite this article
Liu, Y., Li, W., Li, X. et al. Expression and significance of biglycan in endometrial cancer. Arch Gynecol Obstet 289, 649–655 (2014). https://doi.org/10.1007/s00404-013-3017-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-013-3017-3